Vicuron (NASDAQ:MICU)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Vicuron Charts. Click Here for more Vicuron Charts.](/p.php?pid=staticchart&s=N%5EMICU&p=8&t=15)
Vicuron Pharmaceuticals to Present at the Bear Stearns 2005
Healthcare Conference and the Banc of America Securities Healthcare Conference
KING OF PRUSSIA, Pa., May 9 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals
Inc. (Nasdaq: MICU; Nuovo Mercato) today announced that it will participate at
the following upcoming investor conferences:
Bear Stearns 2005 Healthcare Conference
Dov A. Goldstein, M.D., Vicuron's Executive Vice President and CFO, will
present at the Bear Stearns Healthcare Conference at 9:30 a.m. Greenwich Mean
Time (GMT) tomorrow, May 10, 2005 at the Four Seasons Hotel in London, England.
Banc of America Securities Health Care Conference 2005
Dov A. Goldstein, M.D., Vicuron's Executive Vice President and CFO, will
present at the Banc of America Securities Health Care Conference at 4:00 p.m.
Pacific Time (PT) on Wednesday, May 18, 2005 at the Four Seasons Hotel in Las
Vegas, Nevada.
To access the live audio broadcast or the subsequent archived recording log on
to http://www.vicuron.com/ and click on the investor relations section. Please
connect to the website several minutes prior to the start of the webcast to
ensure adequate time for any software download that may be necessary. The live
broadcasts will be archived for 7 days.
About Vicuron Pharmaceuticals
Vicuron Pharmaceuticals is a biopharmaceutical company focused on discovering,
developing, manufacturing and commercializing vital medicine for seriously ill
patients. The company has two New Drug Applications submitted to the U.S. Food
and Drug Administration for its lead products, dalbavancin, a novel intravenous
antibiotic for the treatment of serious Gram-positive infections, and
anidulafungin, a novel antifungal agent. Vicuron applies a disciplined,
integrated approach to anti-infective discovery for next-generation compounds
in both hospital-based and community-acquired infections. In addition, the
company has research and development collaborations with leading pharmaceutical
companies, such as Pfizer.
Forward-Looking Statements This presentation contains forward-looking
statements that predict or describe future events or trends. The matters
described in these forward-looking statements are subject to known and unknown
risks, uncertainties and other unpredictable factors, many of which are beyond
Vicuron's control. Vicuron faces many risks that could cause its actual
performance to differ materially from the results predicted by its
forward-looking statements, including the possibilities that clinical trials
and the results thereof might be delayed or unsuccessful, that the timing of
the filing of any new drug application or any amendment to a new drug
application might be delayed, that clinical trials might indicate that a
product candidate is unsafe or ineffective, that the FDA might require
additional information to be submitted and additional actions to be taken
before it will make any decision, that any filed new drug application may not
be approved by the FDA, that ongoing proprietary and collaborative research
might not occur or yield useful results, that the pipeline may not yield a new
clinical candidate or a commercial product, that a third party may not be
willing to license Vicuron's product candidates on terms acceptable to it or at
all, that competitors might develop superior substitutes for Vicuron's products
or market these competitive products more effectively, that a sales force may
not be developed as contemplated and that one or more of Vicuron's product
candidates may not be commercialized successfully. The reports that Vicuron
files with the U.S. Securities and Exchange Commission contain a fuller
description of these and many other risks to which Vicuron is subject. Because
of those risks, Vicuron's actual results, performance or achievements may
differ materially from the results, performance or achievements contemplated by
its forward-looking statement. The information set forth in this presentation
represents management's current expectations and intentions. Vicuron assumes no
responsibility to issue updates to the forward-looking matters discussed in
this news release.
DATASOURCE: Vicuron Pharmaceuticals Inc.
CONTACT: Dov A. Goldstein, M.D. of Vicuron Pharmaceuticals Inc.,
+1-610-205-2312, or ; or E. Blair Schoeb of WeissComm
Partners, +1-212-923-6737, or ; or Heather May of
Burns McClellan Inc., +1-212-213-0006, or , both for Vicuron
Pharmaceuticals Inc.
Web site: http://www.vicuron.com/